



SCYNEXIS to Participate in the Cantor Antibiotics Summit

January 11, 2018

JERSEY CITY, N.J., Jan. 11, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in a panel entitled "Novel Ways to Treat and/or Address Infections" at the Cantor Antibiotics Summit at the Omni Berkshire Hotel, New York, on Wednesday, January 17, 2018 at 12:15 p.m. ET.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, [SCY-078](#), is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of several serious and life-threatening invasive fungal infections caused by *Candida* and *Aspergillus* species. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations

Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com

Media Relations

Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
cduong@macbiocom.com

Cision View original content: <http://www.prnewswire.com/news-releases/scynexis-to-participate-in-the-cantor-antibiotics-summit-300581688.html>

SOURCE SCYNEXIS, Inc.